Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure

Furihata Takaaki; Kinugawa Shintaro; Fukushima Arata; Takada Shingo; Homma Tsuneaki; Masaki Yoshihiro; Abe Takahiro; Yokota Takashi; Oba Koji; Okita Koichi; Tsutsui Hiroyuki

タイトル	en Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure
作成者	en Furihata, Takaaki NRID 1000060782505 en Kinugawa, Shintaro NRID 1000060399871 en Fukushima, Arata NRID 1000040706553 en Takada, Shingo NRID 1000060722329 en Homma, Tsuneaki en Masaki, Yoshihiro en Abe, Takahiro en Yokota, Takashi NRID 1000090374321 en Oba, Koji NRID 1000030422926 en Okita, Koichi NRID 1000080382539 en Tsutsui, Hiroyuki NRID 1000070264017
アクセス権	open access
権利情報	en © 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ https://creativecommons.org/licenses/by-nc-nd/4.0/ en Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
主題	Other en Heart failure Other en Myostatin Other en Muscle wasting NDC 490
内容注記	Abstract en Background: It has been reported that skeletal muscle mass and strength are decreased in patients with heart failure (HF), and HF is associated with both reduced exercise capacity and adverse clinical outcomes. Myostatin has been known as a negative regulator of muscle growth, follistatin as the myostatin antagonist, maintaining tissue homeostasis. We thus determined serum myostatin levels in HF patients and whether they are associated with skeletal muscle wasting. Methods and results: Forty one consecutive HF patients (58 +/- 15 years old, New York Heart Association class I-III) and 30 age-matched healthy subjects as controls (53 +/- 8 years old) were studied. Serum myostatin levels were significantly lower in HF patients than controls (18.7 +/- 7.4 vs. 23.6 +/- 5.2 ng/mL, P < 0.001). Circumference of the thickest part of the right thigh was significantly small (468 +/- 72 vs. 559 +/- 37 mm, P = 0.001) and lower extremity muscular strength was lower in patients with HF (129 +/- 55 vs. 219 +/- 52 N × m, P < 0.001). Fourteen HF patients (34%) had muscle wasting. By univariate analysis, higher age, higher serum follistatin, and lower serum myostatin were significantly associated with the presence of muscle wasting. By multivariate analysis, serum myostatin levels were independently associated with muscle wasting (OR = 0.77, 95% CI [0.58, 0.93], P = 0.02). Conclusion: Serum myostatin levels were significantly decreased in HF patients and associated with lower extremity muscle wasting, suggesting that myostatin may be an important factor for maintaining skeletal muscle mass and strength in HF.
出版者	en Elsevier
日付	Issued2016-10-01
言語	eng
資源タイプ	journal article
出版タイプ	AM
資源識別子	HDL http://hdl.handle.net/2115/67234
関連	isVersionOf DOI https://doi.org/10.1016/j.ijcard.2016.06.231 PMID 27390974
収録誌情報	PISSN 0167-5273 en International journal of cardiology 巻220 開始ページ483 終了ページ487
ファイル	fulltext IntJCardiol220_483.pdf 338.45 KB (application/pdf) Issued2016-10-01
コンテンツ更新日時	2023-07-26